Man Group

Man Group’s Whitehawk Therapeutics WHWK Stock Holding History

Man Group’s Portfolio WHWK Stock Details WHWK Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q1	–	Sell	-14,484	Closed	-$45.7K	–	2417
2024 Q4	$45.7K	Sell	14,484 -11	-0.1%	-$25	﹤0.01%	1949
2024 Q3	$29.9K	Buy	+14,495	New	+$23.4K	﹤0.01%	1931

Other funds holding WHWK

QVT Financial New York $1.37B AUM 148.1% 1-Year Est. Return

OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return

Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return

Acuta Capital Partners Redwood City, California $142M AUM 783.79% 1-Year Est. Return

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return

Siren LLC Greenwich, Connecticut $3.61B AUM 203.3% 1-Year Est. Return

Yu Fan $97M AUM 57.2% 1-Year Est. Return

BML Capital Management Zionsville, Indiana $156M AUM 129.82% 1-Year Est. Return

Acorn Capital Advisors New York $352M AUM 299.18% 1-Year Est. Return

Man Group's WHWK Position: Q1 2025 in Review

Man Group sold out of Whitehawk Therapeutics (WHWK) in Q1 2025, closing a stake of 14,484 shares — an estimated $45.7K sold.

Man Group first reported a position in WHWK in Q3 2024 and held it in 2 quarters. The position peaked at $45.7K in Q4 2024. 50 funds tracked by Wall St. Rank hold WHWK as of Q1 2025.

Man Group reported no remaining Whitehawk Therapeutics position as of Q1 2025 after selling out during the quarter.
Man Group sold 14,484 Whitehawk Therapeutics shares in Q1 2025, an estimated $45.7K.
Man Group first reported a position in Whitehawk Therapeutics in Q3 2024 and held it in 2 quarters.
Man Group's Whitehawk Therapeutics position peaked at $45.7K in Q4 2024.
50 funds tracked by Wall St. Rank held Whitehawk Therapeutics as of Q1 2025.

Based on Man Group's 13F filing for Q1 2025, filed 15 May 2025.